Consistent Glycemic Efficacy and Safety of Concomitant Use of iGlarLixi and Sodium-Glucose Cotransporter-2 Inhibitor Therapy for Type 2 Diabetes-A Patient-Level Pooled Analysis

被引：0
|
作者：
Giorgino, Francesco
Guja, Cristian
Davies, Melanie J.
Aydin, Hasan
Lauand, Felipe
Souhami, Elisabeth
Melas-Melt, Lydie
Aroda, Vanita R.
Rosenstock, Julio
机构：
来源：
DIABETES | 2023年 / 72卷
关键词：
D O I：
10.2337/db23-773-P
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
773-P
引用
收藏
页数：4
相关论文
共 50 条
  • [1] Consistent glycaemic efficacy and safety of concomitant use of iGlarLixi and sodium-glucose co-transporter-2 inhibitor therapy for type 2 diabetes: A-level of three randomised clinical trials
    Giorgino, Francesco
    Guja, Cristian
    Aydin, Hasan
    Lauand, Felipe
    Melas-Melt, Lydie
    Rosenstock, Julio
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2024, 209
  • [2] Ertugliflozin: a sodium-glucose cotransporter-2 (SGLT-2) inhibitor for glycemic control in type 2 diabetes
    Derosa, Giuseppe
    Maffioli, Pamela
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2018, 14 : 1637 - 1640
  • [3] Efficacy and Safety of Bexagliflozin, a Selective Sodium-Glucose Cotransporter-2 Inhibitor, in Type 2 Diabetes: A Systematic Review and Meta-Analysis
    Kamrul-Hasan, A. B. M.
    Dutta, Deep
    Mondal, Ershad
    Nagendra, Lakshmi
    Hasan, Mehedi
    Shahidullah, Md.
    Biswas, Kaushik
    Bhattacharya, Saptarshi
    CLINICAL DIABETOLOGY, 2025,
  • [4] Efficacy and safety of sodium-glucose cotransporter-2 inhibitors in type 2 diabetes mellitus with inadequate glycemic control on metformin: a meta-analysis
    Zhang Jingfan
    Li Ling
    Liu Cong
    Li Ping
    Chen Yu
    ARCHIVES OF ENDOCRINOLOGY METABOLISM, 2019, 63 (05): : 478 - 486
  • [5] Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With CKD and Type 2 Diabetes
    Fu, Edouard
    D'Andrea, Elvira
    Wexler, Deborah J.
    Patorno, Elisabetta
    Paik, Julie M.
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2022, 33 (11): : 673 - 673
  • [6] EFFICACY AND SAFETY OF SODIUM-GLUCOSE COTRANSPORTER-2 INHIBITORS IN TYPE 2 DIABETES MELLITUS WITH INADEQUATE GLYCEMIC CONTROL ON INSULIN: A NETWORK META-ANALYSIS
    Shestakova, Marina, V
    Galstyan, Gagik R.
    Kvasnikov, Boris B.
    Erina, Ekaterina E.
    DIABETES MELLITUS, 2024, 27 (06): : 543 - 554
  • [7] Comparison of Efficacy and Safety Profile of Sodium-Glucose Cotransporter-2 Inhibitors as Add-On Therapy in Patients With Type 2 Diabetes
    Hussain, Mazhar
    Elahi, Asim
    Iqbal, Javed
    Ghafoor, Muhammad
    Rehman, Habib
    Akhtar, Shoaib
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2021, 13 (04)
  • [8] Finerenone in Predominantly Advanced CKD and Type 2 Diabetes With or Without Sodium-Glucose Cotransporter-2 Inhibitor Therapy
    Rossing, Peter
    Filippatos, Gerasimos
    Agarwal, Rajiv
    Anker, Stefan D.
    Pitt, Bertram
    Ruilope, Luis M.
    Chan, Juliana C. N.
    Kooy, Adriaan
    McCafferty, Kieran
    Schernthaner, Guntram
    Wanner, Christoph
    Joseph, Amer
    Scheerer, Markus F.
    Scott, Charlie
    Bakris, George L.
    KIDNEY INTERNATIONAL REPORTS, 2022, 7 (01): : 36 - 45
  • [9] Euglycemic diabetic ketoacidosis in type 2 diabetes treated with a sodium-glucose cotransporter-2 inhibitor
    Jazi, Mazen
    Porfiris, George
    CANADIAN FAMILY PHYSICIAN, 2016, 62 (09) : 722 - 724
  • [10] Perioperative Considerations for the Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes
    Peacock, Sharon C.
    Lovshin, Julie A.
    Cherney, David Z. I.
    ANESTHESIA AND ANALGESIA, 2018, 126 (02): : 699 - 704
12345